- Category: Search for a Cure
- Published on Friday, 07 March 2014 00:00
- Written by Liz Highleyman
HIV has re-emerged in 2 Boston men who underwent experimental antiretroviral therapy (ART) interruption after receiving bone marrow stem cell transplants for cancer treatment, Timothy Henrich reported at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this week in Boston. These cases suggest that a functional cure for HIV will be difficult to achieve if even a small amount of residual virus remains in the body.
Henrich and Daniel Kuritzkes from Brigham and Women’s Hospital first reported on the Boston patients at the 2012 International AIDS Conference, with more detailed follow-up presented at the International AIDS Society meeting last July.
The 2 men received donor bone marrow containing hematopoietic stem cells, which give rise to all types of blood cells including the CD4 T-cells that harbor HIV. Both men's donors had normal or "wild-type" stem cells susceptible to HIV infection. These cases therefore differ from that of the Berlin Patient, who apparently remains HIV-free 7 years after stem cell transplants from a donor with a double mutation (CCR5-delta-32) that makes cells resistant to HIV entry. However, the Boston patients themselves carried a single copy of the protective mutation.
Also unlike the Berlin Patient, the Boston men received what Henrich called a "kinder and gentler" reduced-intensity chemotherapy conditioning regimens that did not kill off all their original immune cells. This enabled them to remain on antiretroviral therapy throughout the transplant process.
The transplants were successful and the men's own blood cells were progressively replaced by donor cells. Both men maintained viral suppression after the procedure, and frequent and extensive testing over the next few years showed very low levels of HIV. Not only did plasma HIV RNA remain undetectable, but the virus also could not be found in large volumes of peripheral blood mononuclear cells (PBMCs), lymph nodes, or gut tissue using the most sensitive assays.
After the men had been apparently HIV-free for 2.6 and 4.3 years, they and their providers agreed to try an analytical treatment interruption to see if the virus would return.
At the 2013 IAS meeting Henrich reported that the men continued to have undetectable plasma HIV RNA and undetectable integrated HIV DNA in PBMCs after 7 and 15 weeks off ART, raising hopes that the stem cell transplant process might contribute to a functional cure.
But these hopes turned to disappointment when Henrich reported last December at the International Workshop on HIV Persistence in Miami that HIV had come back in both men.
- The first patient experienced HIV re-emergence 12 weeks into his treatment interruption, while the second man did not show signs of HIV rebound until he had been off ART for 8 months.
- Once HIV was detected, both men experienced rapid HIV replication, reaching viral loads in the millions; both also had detectable HIV in their cerebrospinal fluid.
- The men developed symptoms of acute retroviral syndrome similar to those sometimes seen when people first become infected.
- Both patients restarted antiretroviral treatment after viral rebound; one had developed a new NNRTI resistance mutation and switched to a different fully active ART regimen.
- Both men were able to regain viral suppression, their symptoms rapidly resolved, their CD4 counts recovered, and they are doing well.
"Allogeneic hematopoietic stem cell transplantation can result in loss of detectable HIV-1 from blood and gut tissue and antiretroviral-free HIV-1 remission for variable duration," but "viral rebound occurred despite a reduction in reservoir size...of at least 3 log," the researchers summarized.
They suggested that long-lived tissue reservoirs that are inaccessible to testing -- perhaps including host macrophages which are replaced by donor cells more slowly than T-cells after transplant -- may have contributed to viral rebound.
Viruses detected after rebound was genetically similar, suggesting they were clones of only one or a few residual viruses remaining after transplantation. This implies that even a few remaining HIV-infected cells may be enough to allow full viral rebound once protective ART is stopped.
Speaking at a community cure workshop preceding the Retrovirus Conference, Henrich explained that mathematical models indicate that if only 1 HIV-infected cell remains, the chance of a cure is high. If 10 cells remain, viral rebound could take 10 years. If there are 100 residual cells left, rebound could still take up to 3 years.
While these outcomes are disappointing, they shed further light on HIV persistence and how it might be overcome to enable a functional cure without risky stem cells transplants. To date, it remains unclear what factors contributed to temporary HIV remission, what triggered viral rebound, or why one patient was able to remain off ART for so much longer than the other.
The researchers saw no increase in the strength of HIV-specific antibody responses prior to viral rebound. The graft-versus-host reaction -- in which donor cells attack host tissues -- may have played a role in continued surveillance and clearance of residual HIV-infected recipient cells, the researchers suggested. As reported in a related poster, Henrich said that chemotherapy may play some role, "but by itself it doesn't seems to be doing too much."
"Analytic treatment interruption] remains the most reliable measure of viral persistence," the researchers concluded. "Defining the nature and half-life of HIV-1 reservoirs is essential in order to achieve durable antiretroviral-free remission."
TJ Henrich, E Hanhauser, MN Sirignano, et al. HIV-1 Rebound Following Allogeneic Stem Cell Transplantation and Treatment Interruption. 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014). Boston, March 3-6. Abstract 144LB.
TJ Henrich, E Hanhauser, JZ Li, et al. Impact of Systemic Cytotoxic Chemotherapy for Malignancies On HIV-1 Reservoir Persistence. 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014). Boston, March 3-6. Abstract 418.